Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.38 |
| ▸ | SLC12A5 | Q9H2X9 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579027 | 0.96 | CRHR1 (0.35) | CRHR1PI4KBSLC12A5ALDH1A1TP53 | |
| SCHEMBL3557687 | 0.80 | PTGDR2 (0.42) | CRHR1PI4KBALDH1A1TP53GAA | |
| SCHEMBL3436225 | 0.79 | SMN1; SMN2 (0.47) | PI4KBALDH1A1GAARAB9AMEN1 | |
| SCHEMBL3436205 | 0.76 | PTGDR2 (0.38) | CRHR1PI4KBALDH1A1TP53GAA | |
| SCHEMBL18674691 | 0.75 | ALDH1A1 (0.35) | CRHR1SLC12A5ALDH1A1TP53GAA | |
| SCHEMBL13999555 | 0.75 | RAB9A (0.46) | ALDH1A1GAARAB9AMEN1KMT2A | |
| SCHEMBL18678194 | 0.74 | CRHR1 (0.42) | CRHR1ALDH1A1TP53GAARAB9A | |
| SCHEMBL3435734 | 0.72 | PI4KB (0.34) | CRHR1PI4KBALDH1A1TP53GAA | |
| SCHEMBL10278264 | 0.72 | LMNA (0.37) | CRHR1ALDH1A1TP53GAARAB9A | |
| SCHEMBL3573088 | 0.71 | CHI3L1 (0.41) | CRHR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163746-B2 | Azolecarboxamide derivative | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286766-A1 | AZOLECARBOXAMIDE DERIVATIVE | GPR17, NTRK1, TRPV1 | CRHR1 2390/4885PI4KB 1652/4885SLC12A5 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.